COMMUNIQUÉS West-GlobeNewswire

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
24/10/2026
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s [...]
Beyond Elizabeth Holmes: Ryan El Hosseiny Thanks Nathan Fielder for Shining a Light on Cancer Research
23/10/2026
MIAMI, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Featured as “The Billboard Guy” in Nathan Fielder's documentary, You Can See Everything , biochemist, entrepreneur and Just Blood founder Ryan El Hosseiny welcomes the spotlight [...]
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
23/10/2026
First-in-human data for ARR-217 selected as a late-breaking oral presentation ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., [...]
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
23/10/2026
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity [...]
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
23/10/2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the [...]
The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026
23/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
J-Star Holding Co., Ltd. Files Interim Financial Report on Form 6-K
23/10/2026
Company is Highlighting Strategic Focus on U.S. Opportunities, Balance Sheet Improvement, and Management Commitment TAICHUNG, Taiwan and HOUSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT [...]
Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs
23/10/2026
Cette collaboration vise à améliorer la planification des essais cliniques et à élargir l’accès des patients aux études ciblées par biomarqueurs en Australie Points clés Cette collaboration vise à accélérer la recherche [...]
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
23/10/2026
Price barriers are falling, as improving technicals meet a string of clinical, international, and regulatory milestones with November 17’s FDA meeting next on the calendar. DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- ( [...]
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
23/10/2026
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient [...]
Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaire
23/10/2026
Sous réserve de son approbation, l’association TALVEY ® et daratumumab constituerait la seule association thérapeutique comprenant un anticorps bispécifique ciblant le GPRC5D dans le traitement du myélome multiple en [...]
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
23/10/2026
Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix ® was generally [...]
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
23/10/2026
Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel IL-4Rα/TSLP bispecific [...]
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
23/10/2026
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone Median rPFS was 9.1 months and rPFS6 was 62.5% in [...]
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
23/10/2026
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial–mesenchymal transition (EMT), and AR-low/proliferative. The AR-high/ [...]
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
23/10/2026
Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies [...]
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
23/10/2026
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over [...]
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
23/10/2026
Durable responses observed across multiple tumor types during dose escalation MGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patients [...]
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
23/10/2026
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum